A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
N-methyl-d-aspartate receptors (NMDARs) are glutamate-gated ion channels that play key roles in brain physiology and pathology. Because numerous pathologic conditions involve NMDAR overactivation, subunit-selective antagonists hold strong therapeutic potential, although clinical successes remain limited. Among the most promising NMDAR-targeting drugs are allosteric inhibitors of GluN2B-containing receptors. Since the discovery of ifenprodil, a range of GluN2B-selective compounds with strikingly different structural motifs have been identified. This molecular diversity raises the possibility of distinct binding sites, although supporting data are lacking. Using X-ray crystallography, we show that EVT-101, a GluN2B antagonist structurally unrelated to the classic phenylethanolamine pharmacophore, binds at the same GluN1/GluN2B dimer interface as ifenprodil but adopts a remarkably different binding mode involving a distinct subcavity and receptor interactions. Mutagenesis experiments demonstrate that this novel binding site is physiologically relevant. Moreover, in silico docking unveils that GluN2B-selective antagonists broadly divide into two distinct classes according to binding pose. These data widen the allosteric and pharmacological landscape of NMDARs and offer a renewed structural framework for designing next-generation GluN2B antagonists with therapeutic value for brain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · cited 2×
“The Glide standard precision (small-molecule drug discovery suite 2015-3, 2015; Friesner et al., 2004) protocol was used to dock the ligands into the protein active site.”
BackgroundMethodGlutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 3×
“NMDARs are heterotetramers usually associating two GluN1 and two GluN2 subunits (Traynelis et al., 2010; Paoletti et al., 2013).”
BackgroundMonyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535 · cited 1×
“D), control a wide range of the receptor ’ s functional properties and are differentially expressed throughout the central nervous system (Monyer et al., 1994; Sheng et al., 1994; Paoletti, 2011).”
BackgroundNMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523 · cited 5×
“NMDARs are heterotetramers usually associating two GluN1 and two GluN2 subunits (Traynelis et al., 2010; Paoletti et al., 2013).”
BackgroundInfluentialSelf-citationChanging subunit composition of heteromeric NMDA receptors during development of rat cortex
Sheng, M., Cummings, J., Roldan, L. A., Jan, Y. N., & Jan, L. Y. (1994) · Nature · doi:10.1038/368144a0 · Cited by 1,377 · cited 1×
“D), control a wide range of the receptor ’ s functional properties and are differentially expressed throughout the central nervous system (Monyer et al., 1994; Sheng et al., 1994; Paoletti, 2011).”
BackgroundIbrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 2×
“Many, such as CP-101,606 (Traxoprodil; Chenard et al., 1995), Ro25-6981 (Fischer et al., 1997), or besonprodil (Chizh et al., 2001), share the same phenylethanolamine scaffold as ifenprodil.”
Background
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Structure, function, and allosteric modulation of NMDA receptors
Hansen, K. B., Yi, F., Perszyk, R. E., Furukawa, H., Wollmuth, L. P., Gibb, A. J., & Traynelis, S. F. (2018) · Journal of General Physiology · doi:10.1085/jgp.201812032 · Cited by 573
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Wu, J., Gao, L., Shang, L., Wang, G., Wei, N., Chu, T., Chen, S., Zhang, Y., Huang, J., Wang, J., et al. (2017) · Fitoterapia · doi:10.1016/j.fitote.2017.03.015 · Cited by 25
Reversible Control of Native GluN2B-Containing NMDA Receptors with Visible Light
Geoffroy, C., Berraud-Pache, R., Chéron, N., McCort-Tranchepain, I., Doria, J., Paoletti, P., & Mony, L. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00247 · Cited by 9
Self-citation
Metadata
- Authors
- Stroebel, D., Buhl, D. L., Knafels, J. D., Chanda, P. K., Green, M., Sciabola, S., Mony, L., Paoletti, P., & Pandit, J.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 89
- Issue
- 5
- Pages
- 541-551
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2294208894
- Cited by
- 108
- References
- 6
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists. https://app.cochat.ai/papers/10.1124/mol.115.103036
- The paper
- Stroebel, D., Buhl, D. L., Knafels, J. D., Chanda, P. K., Green, M., Sciabola, S., Mony, L., Paoletti, P., & Pandit, J. (2016). A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists. Molecular Pharmacology. https://doi.org/10.1124/mol.115.103036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.